- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02027883
Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD) (VF)
Comparison of Ventricular Fibrillation Induction Techniques During Medtronic Implantable Cardioverter Defibrillator Implant
As the indications for Implantable Cardioverter Defibrillator implantation expand, minimizing implant time is critical. Also, patients receiving biventricular ICDs are sometimes more unstable and minimization of sedation time is crucial. Multiple induction attempts, with a 1-Joule shock, can cause disruption in lead position. Therefore limiting the number of attempts will allow for better lead stability throughout the procedure and a more straightforward implant process.
Investigator proposes a detailed documentation of success rates from various Ventriculart Fibrillation induction methods during implant of Medtronic defibrillation capable devices.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Our clinical experience has found that attempts to induce patients receiving ICDs at implant using the nominal Medtronic T-shock settings are not always effective at inducing ventricular fibrillation. When this results, a change to the parameters for T-shock is made before reattempting to induce ventricular fibrillation in patients undergoing ICD implantation.
Another available induction method is 50 Hz Burst. "The 50 Hz Burst induction is designed to induce VF by delivering a rapid burst of pacing pulses. The amplitude and pulse width of these pulses are selectable, but the pacing interval is fixed at 20 ms."2 If multiple attempts using the T-shock method are unsuccessful, 50 Hz Burst provides an additional method for inducing ventricular fibrillation. It is a less desirable method since it can result in very fine VF that is difficult to identify the initiation of possibly resulting in longer times in VF causing higher defibrillation threshold or in undersensing due to the fine nature of the rhythm.
T-shock has been found to be a fast and reliable method for inducing ventricular fibrillation in ICD implants. Greater success of inducing ventricular fibrillation using the T-shock method has been found when the energy of the T-shock was higher and the coupling interval was shorter. In addition, increasing the shock strength increases the window of vulnerability. For the T-shock method to be most efficient, initial success at inducing ventricular fibrillation, and therefore a reduced number of attempts, is important. This requires a better understanding of the optimal programmed settings for the initial T-shock induction attempt.
Moreover, in recent years, ICD indications have grown to include primary prevention patients. These patients may have different vulnerable periods than patients previously evaluated to develop Medtronic nominal settings.
Our clinical experience has found that the nominal T-shock settings are only effective at inducing ventricular fibrillation approximately seventy-five percent of the time. However, a detailed collection of success rates has not been performed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
- Wellmont CVA Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients undergoing Medtronic ICD or Cardiac Resynchronization Therapy-Defibrillator implant (initial implant or generator replacement) will be included.
Exclusion Criteria:
- Any patient who is medically unstable and testing is deemed unsafe by physician will be excluded from this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nominal Parameter
Nominal T shock setting
|
Nominal Parameter Set 1 Programming Values for EnTrust
Other Names:
|
|
Experimental: Experimental Parameter
Educated T shock setting
|
Experimental Parameter Set 2 Programming Values
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sustained Ventricular Fibrillation
Time Frame: 2 hours
|
The primary endpoint is the successful induction of sustained ventricular fibrillation.
|
2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Factors
Time Frame: 2 hours
|
Determine if any pre-implant patient demographics are factors impacting T-shock success according to parameter settings.
|
2 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety Monitoring
Time Frame: 2 hours
|
Number of participants that were monitored for safety issues, including increased heart rate, blood pressure, decreased oximetry levels, and stable rhythm during the entire procedure.
|
2 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Bardy G, Mehra R, Johnson G, Kudenchuk P, Dolack G, Poole J, Hofer B: Low energy pulsing on the T-wave: A new programming method for intentional, device mediated induction of ventricular fibrillation for defibrillation testing. PACE 15(4, Pt II): 562, 1992.
- Bhandari AK, Isber N, Estioko M, Ziccardi T, Cannom DS, Park Y, Lerman RD, Prejean C, Sun GW. Efficacy of low-energy T wave shocks for induction of ventricular fibrillation in patients with implantable cardioverter defibrillators. J Electrocardiol. 1998 Jan;31(1):31-7. doi: 10.1016/s0022-0736(98)90004-8.
- Marquis DR Reference Manual, Medtronic, Inc.
- Mitchell L, Yee R, Talajic M, Newman D, Sheldon R, Kerr C, Kus T, Boyle A, Canadian Jewel PCD Investigators: Low-energy, T-wave synchronous, interval shock for rapid, reliable ventricular fibrillation induction by an implantable cardioverter defibrllattor. PACE, 17(4, Pt II): 851, 1994.
- Swartz J, Stanton M, DeGroot P, Mehra R: Influence of T-wave shock energy on ventricular fibrillation vulnerability in humans. JACC 1995 Conference Abstracts: 214A, 1995.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VF Induction
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy
-
University of AberdeenNHS GrampianCompletedTako-tsubo CardiomyopathyUnited Kingdom
-
RenJi HospitalNot yet recruitingHypertrophic Cardiomyopathy (HCM) | Restrictive Cardiomyopathy | Metabolic Cardiomyopathy | Dilated Cardiomyopathy (DCM)China
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsUnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)United States
-
University of California, IrvineWithdrawnDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction CardiomyopathyUnited States
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
Shanghai Zhongshan HospitalNot yet recruitingCardiovascular Diseases | Myocarditis | Cardiomyopathies | Ischemic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Hypertrophic Cardiomyopathy (HCM) | Restrictive Cardiomyopathy | Amyloid Cardiomyopathy | Dilated Cardiomyopathy (DCM)
-
Xiang WeiActive, not recruitingTransapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNonobstructive Hypertrophic CardiomyopathyChina
-
ProlaioRecruitingHeart Failure | Hypertension | Aortic Stenosis | Dilated Cardiomyopathy | Cardiovascular Disease (CVD) | Aortic Stenosis Disease | Dilated Cardiomyopathy, Familial | Hypertension (HTN) | Dilated Cardiomyopathy (DCM) | Hypertrophic Cardiomyopathy Patients | Hypertrophic Cardiomyopathy, Obstructive | Hypertrophic...United States
-
German Heart InstituteDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)UnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Noncompaction | Primary CardiomyopathyGermany
-
University Medical Center GroningenAstraZenecaCompletedHeart Failure | Cardiomyopathy, Familial | Phospholamban R14del CardiomyopathyNetherlands
Clinical Trials on Nominal T shock setting
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCompletedErectile DysfunctionUnited States
-
University of Central FloridaNational Institute on Drug Abuse (NIDA)TerminatedHIV | Substance Use Disorder (SUD)United States
-
Deutsches Herzzentrum MuenchenCompletedDefibrillation Testing - ICD Therapy OptimisationGermany
-
Medisch Spectrum TwenteFoothills Medical CentreRecruitingCardiovascular Diseases | Quality of Life | Surgery | Physical Inactivity | SternotomyNetherlands
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingBone Metastases | Lung Metastases | HER2-positive Breast Cancer | Liver Metastases | Stage IV Breast Cancer | Recurrent Breast Cancer | Soft Tissue MetastasesUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingTriple Negative Breast CancerUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Not yet recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Positive Breast Carcinoma | Oligometastatic Breast Carcinoma